Open Access
Tableau I.
Anticorps bispécifiques activateurs des cellules immunes cytotoxiques. PC: préclinique ; Ph. 1: phase clinique 1 ; Ph. II: phase clinique II.
| Mécanisme d’action | Format | Cibles | Molécule | Stade de développement |
|---|---|---|---|---|
| Reciblage des LT cytotoxiques | BiTE Knob-into-hole Knob-into-hole 2:1 TCB Knob-into-hole DART Duobody BiTE Duobody 2:1 TCB DART |
CD19xCD3 CD20xCD3 CD20xCD3 CD20xCD3 CD123xCD3 CD123xCD3 CD123xCD3 BCMAxCD3 BCMAxCD3 CEAxCD3 B7H3xCD3 |
Blinatumomab XmAb13676 Mosunétuzumab CD20-TCB Xmab14045 Flotétuzumab JNJ-63709178 BI 836909 JNJ-64007957 CEA-TCB MGD009 |
Approuvé Ph. I Ph. I Ph. I Ph. I Ph. I Ph. I Ph. I Ph. I Ph. I Ph. I |
| Reciblage des LTgδ | Tandem de Nb Tandem de Nb |
EGFRxδ2 HER2/neuxg9 |
N.A. N.A. |
PC PC |
| Reciblage des cellules NK | Tandab Tandab triKE aTriFlex BiKE IgG-like |
CD30xCD16 BCMAxCD16 CD133xCD16 BCMAxCD200xCD16 CS1xNKG2D CD20xNKp46 |
AFM13 AFM26 N.A. N.A. N.A.- |
Ph. II PC PC PC PC PC |
Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.
Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.
Initial download of the metrics may take a while.